Myelodysplastic syndrome with chromosome 5 abnormalities: A nationwide survey in Japan

Leukemia

Volumn 22, Issue 10, 2008, Pages 1874-1881

  Tasaka, T ^a   Tohyama, K ^a   Kishimoto, M ^b   Ohyashiki, K ^c   Mitani, K ^d   Hotta, T ^e   Kanamaru, A ^f   Okamoto, S ^g   Karasawa, M ^h   Kimura, A ⁱ   Tomonaga, M ^j   Uchiyama, T ^k   Ozawa, K ^l  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Kawasaki College of Allied Health Professions   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KEIO UNIVERSITY   (Japan)

^h GUNMA UNIVERSITY   (Japan)

ⁱ HIROSHIMA UNIVERSITY   (Japan)

^j NAGASAKI UNIVERSITY   (Japan)

^k KYOTO UNIVERSITY   (Japan)

^l JICHI MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 5; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION 5; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INCIDENCE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; JAPAN; KARYOTYPING; LEUKEMIA; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; THROMBOCYTE TRANSFUSION;

EID: 54049096659     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.199     Document Type: Article

References (30)

1. Nimer SD, Golde DW. The 5q- abnormality. Blood 1987; 70: 1705-1712.
2. Van den Berghe H, Michaux L. 5q-, twenty-five years later: A synopsis. Cancer Genet Cytogenet 94: 1-7.
3. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004; 18: 113-119.
4. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q- syndrome. Hematology 2004; 9: 271-277.
5. Van den Aerghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974; 251: 437-438.
6. Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 2005; 84: 569-571.
7. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic, factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
8. Van den Berghe H, Vermaelen K, Mecucci C, Barbieri D, Tricot G. The 5q- anomaly. Cancer Genet Cytogenet 1985; 17: 189-255.
9. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
10. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849.
11. Malcovati L, Germing U, Kuendgen A, Porta D, Pascutto C, Inverinizzi R et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-3510.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
13. Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995; 9: 1491-1498.
14. Mauritzson N, Johansson B, Albin M, Rylander L, Billstrom R, Ahlgren T et al. Survival time in a population-based consecutive series of adult acute myeloid leukemia - the prognostic impact of karyotype during the time period 1976-1993. Leukemia 2000; 14: 1039-1043.
15. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
16. Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U et al Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: An international retrospective study. Blood 2007; 109: 4641-4647.
17. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E et al Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 1993; 7: 1315-1323.
18. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: A multicentric study in Japan. Leukemia 1993; 7: 499-508.
19. Jacobs RA, Combleet M, Vardiman J, Larson R, LeBeau MM, Rowley JD. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986; 67: 1765-1772.
20. Yunis JJ, Lobell M, Arnesen MA, Oken MM, Mayer MG, Rydell RE et al Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol 1988; 68: 189-194.
21. Pierre R, Catovsky D, Mufti G, Swansbury G. Mecucci C, Dewald GW et al. Clinical cytogenetic correlations in myelodysplasia (preleukemia). Cancer Genet Cytogenet 1989; 40: 149-161.
22. Samuels BL, Larson RL, LeBeau MM, Daly KM, Bitter MA, Vardiman JW et al. Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia 1988; 2: 79-83.
23. Kardos G, Baumann I, Passmore SJ, Locatelli F, Haste H, Schultz KR et al. Refractory anemia in childhood: A retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003; 102: 1997-2003.
24. Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003; 17: 305-313.
25. Chen B, Zhao WL, Jin J, Xue YQ Cheng X, Chen XT et al. Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia 2005; 19: 767-775.
26. Sokal G, Michaux JL, van den Berghe H, Cordier A, Rodhain J, Ferrantr A et al. A new hematologic syndrome with a distinct karyotype: The 5q- chromosome. Blood 1975; 46: 519-533.
27. Dewald GW, Davis MP, Pierre RV, O'Fallon JR, Hoagland HC. Clinical characteristics and prognosis of 50 patients with a myeloproliferative syndrome and deletion of part of the long arm of chromosome 5. Blood 1985; 66: 189-197.
28. Haase D, Germing U, Schanz, Pfeilstöcker M, Nösslinger T, Hildebrandt B et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
29. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005; 23: 7594-7603.
30. List AF, Baker AF, Green S, Bellamy W. Lenalidomide: Targeted anemia therapy for myelodysplastic syndromes. Cancer Control 2006; 13 4-11.